D.C. is facing its most urgent threat since it was given the power of Home Rule during the Nixon administration.
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback